T Scientific

At a glance

T Scientific filed 29 disclosures in the last 12 months, including 7 insider, 2 issuance, 1 contract and 1 5% holder. The most recent key filing was on Oct 8: Worth 11.9% of last year's revenue, over about 12 months.

Revenue for 2025 was ₩36.4B, down 15.5% on 2024. Operating margin was 0.7% against -22.9% a year earlier. Debt was 19% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩13.2B and operating loss of ₩1.6B.

The 2025 annual report lists 239 employees with an average tenure of 3.8 years and average pay of ₩49.2M, #1486 of 1,829 listed companies by average pay. Its 6 directors and auditors were paid ₩78M each on average. It paid no cash dividend for 2025. (주)위지트 and related parties held 32.97% at year end.

From the 2025 annual report

Staff: 239 (181 men, 58 women), of whom 19 on fixed-term contracts. Total pay for the year: ₩12.2B. Directors and auditors: 6, paid ₩466M in total.

No cash dividend was paid for 2025.

Largest shareholder

(주)위지트 holds 30.77%; with 5 related parties the group holds 32.97% of common shares at year end (from 32.96% at the start of the year).

Auditor: 현대회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

New contracts, last 12 months

1 new supply contract worth 12% of the revenue stated in the filings.

Amended amounts replace the originals. Subsidiary contracts and terminations are excluded.

Financial summary